We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$173M
AUM Growth
+$11M
Cap. Flow
+$39.8M
Cap. Flow %
23.02%
Top 10 Hldgs %
48.18%
Holding
76
New
24
Increased
16
Reduced
11
Closed
16

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.2M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$5.3M
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$4.37M
4
IMMU
Immunomedics Inc
IMMU
+$4.37M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$4.03M

Top Sells

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$8.74M
2
FOLD
Amicus Therapeutics
FOLD
+$5.81M
3
AVID
Avid Technology Inc
AVID
+$3.07M
4
LMAT icon
LeMaitre Vascular
LMAT
+$3.02M
5
TLGT
Teligent, Inc
TLGT
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 74.16%
2 Consumer Discretionary 2.56%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRNE
26
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$2.52M 1.46%
300,000
+87,598
+41% +$1.4M
OXFD
27
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.49M 1.44%
184,746
-12,934
-7% -$175K
AGEN
28
Agenus
AGEN
$326M
$2.35M 1.36%
25,985
+3,370
+15% +$499K
ARRY
29
DELISTED
Array Biopharma Inc
ARRY
$2.19M 1.27%
+480,020
New +$2.85M
ALIM
30
DELISTED
Alimera Sciences
ALIM
$2.15M 1.25%
64,955
– –
SIOX
31
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.81M 1.05%
17,500
-3,750
-18% -$440K
EPZM
32
DELISTED
Epizyme, Inc
EPZM
$1.8M 1.04%
+140,000
New +$2.83M
EPIX
33
DELISTED
ESSA Pharma
EPIX
$1.8M 1.04%
+14,420
New +$2.01M
LRMR icon
34
Larimar Therapeutics
LRMR
$413M
$1.65M 0.95%
4,293
-115
-3% -$51.8K
TAST
35
DELISTED
Carrols Restaurant Group, Inc.
TAST
$1.53M 0.89%
+128,643
New +$1.53M
CUTR
36
DELISTED
Cutera, Inc.
CUTR
$1.53M 0.89%
116,921
+41,921
+56% +$623K
CLVS
37
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$1.38M 0.8%
+15,000
New +$1.3M
BDSI
38
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.18M 0.68%
+212,100
New +$1.57M
ALBO
39
DELISTED
Albireo Pharma Inc
ALBO
$1.12M 0.65%
84,961
-11,263
-12% -$284K
AUPH icon
40
Aurinia Pharmaceuticals
AUPH
$1.87B
$1.07M 0.62%
377,427
-147,324
-28% -$505K
DCOY
41
Decoy Therapeutics
DCOY
$2.31M
– –
0
– –
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.68B
$1.02M 0.59%
+31,744
New +$1.08M
CBMX
43
DELISTED
CombiMatrix Corporation
CBMX
$1M 0.58%
59,576
+893
+2% +$18K
AGRX
44
DELISTED
Agile Therapeutics
AGRX
$952K 0.55%
71
+7
+11% +$124K
EWA icon
45
PUT
iShares MSCI Australia ETF
EWA
$1.41B
$896K 0.52%
+50,000
New +$979K
EIGR
46
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$861K 0.5%
+1,822
New +$966K
CORV
47
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$780K 0.45%
+92,397
New +$851K
CDTX
48
DELISTED
Cidara Therapeutics
CDTX
$752K 0.44%
2,956
-3,544
-55% -$1.01M
CRDC
49
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$499K 0.29%
184,944
– –
RIGL icon
50
Rigel Pharmaceuticals
RIGL
$693M
$494K 0.29%
+20,000
New +$597K
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2015 Portfolio in Review

As of Q3 2015, Acuta Capital Partners held 76 positions worth $173M, up 6.8% from $162M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Acuta Capital Partners deployed $39.8M of net new capital in Q3 2015, opening 24 new positions and adding to 16 existing holdings. Its largest new stake was Exelixis: 1,880,004 shares worth $10.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 81% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Applied Genetic Technologies Corporation, an estimated $8.74M trimmed.

  • Acuta Capital Partners's largest Q3 2015 buy was Exelixis: 1,880,004 shares worth $10.5M.
  • Acuta Capital Partners added most to NeuroDerm Ltd. Ordinary Shares in Q3 2015, an estimated $4.03M increase.
  • Acuta Capital Partners's biggest Q3 2015 reduction was Applied Genetic Technologies Corporation, cutting an estimated $8.74M.
  • Acuta Capital Partners fully exited Avid Technology Inc in Q3 2015, selling an estimated $3.07M.
  • Acuta Capital Partners's ten largest holdings make up 48% of its $173M portfolio in Q3 2015.
  • Acuta Capital Partners opened 24 new positions and closed 16 in Q3 2015.
  • Acuta Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $173M.

Based on Acuta Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.